New Delhi, July 8
Drug firm Mankind Pharma on Thursday said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of Covid-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy’s Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised Covid-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the Covid-19 patients, it added.
“Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic,” the company said. PTI
Don't MissView All
Several centrally-protected monuments across the country lit...
Harried passengers take to social media to vent their ire at...
'My aim was never to insult people, their relatives': Israeli filmmaker Nadav Lapid apologises for his remarks on The Kashmir Files
Lapid had stirred a massive controversy by terming Vivek Agn...
Gujarat Assembly Elections: 60 pc turnout in Phase 1 covering 83 seats; Congress alleges booth capturing, bogus voting
Voter turnout less than 66.75 pc recorded in first phase of ...
DigiYatra face recognition system launched at 3 airports; Scindia says data stored in encrypted format
DigiYatra will provide seamless entry and embarkation proces...